Rezolute Shares Gain on Positive Ersodetug Indicators Despite Failure to Meet Trial Goals

Dow Jones

01/08

By Elias Schisgall

Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints.

Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year.

Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance.

"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy," Rezolute said Wednesday.

Rezolute said it looks forward to engaging with the Food and Drug Administration in the first quarter to discuss the results.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 07, 2026 11:30 ET (16:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2601807662"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601807662\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601807662?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601807662","market":"hk","top_or_hot":-1,"title":"Rezolute Shares Gain on Positive Ersodetug Indicators Despite Failure to Meet Trial Goals","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of  ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints. \n</p>\n<p>\n  Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year. \n</p>\n<p>\n  Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance. \n</p>\n<p>\n  \"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy,\" Rezolute said Wednesday. \n</p>\n<p>\n  Rezolute said it looks forward to engaging with the Food and Drug Administration in the first quarter to discuss the results. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 07, 2026 11:30 ET (16:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rezolute Shares Gain on Positive Ersodetug Indicators Despite Failure to Meet Trial Goals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRezolute Shares Gain on Positive Ersodetug Indicators Despite Failure to Meet Trial Goals\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-08 00:30</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of  ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints. \n</p>\n<p>\n  Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year. \n</p>\n<p>\n  Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance. \n</p>\n<p>\n  \"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy,\" Rezolute said Wednesday. \n</p>\n<p>\n  Rezolute said it looks forward to engaging with the Food and Drug Administration in the first quarter to discuss the results. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 07, 2026 11:30 ET (16:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RZLT","symbol_name":"Rezolute, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601807662","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601807662","pubTimestamp":1767803400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of  ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints.Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year.Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance.\"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy,\" Rezolute said Wednesday.Rezolute said it looks forwar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RZLT":"Rezolute, Inc.","BK4139":"生物科技"},"translate_title":"尽管未能实现试验目标，Rezolute股价仍因Ersodetug积极指标而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RZLT":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of  ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints. \n\n\n  Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year. \n\n\n  Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance. \n\n\n  \"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy,\" Rezolute said Wednesday. \n\n\n  Rezolute said it looks forward to engaging with the Food and Drug Administration in the first quarter to discuss the results. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2026 11:30 ET (16:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}